We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 656.00 | 5.78% | 12,008.00 | 12,006.00 | 12,012.00 | 12,096.00 | 11,850.00 | 11,890.00 | 2,609,745 | 16:29:59 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.26 | 186.15B |
From Apr 2019 to Apr 2024
By Carla Mozee, MarketWatch
LONDON (MarketWatch) -- U.K. stocks rose Thursday, in broad-based gains that included a higher move for AstraZeneca following regulatory approval of a drug to treat cancer.
The FTSE 100 rose 0.8% to 6,384.51 as all sectors advanced. Most oil and gas stocks continued to build on Wednesday's advance, when the sector staged a turnaround late in the session on a rebound in oil prices. Tullow Oil rose 2.3% and oil-services firm Petrofac Ltd. put in 2.1%, while Royal Dutch Shell PLC swung to a 0.2% rise.
U.S. crude-oil futures on Wednesday came off a five-year low after data showed U.S. crude inventories declined, although the drop was less than forecast.
AstraZeneca PLC shares tacked on 1% as the European Commission approved the company's Lynparza capsules for use by patients with ovarian cancer. The drug may be used in all 28 EU member states, as well as in Norway, Iceland and Liechtenstein.
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
